86 results about "Liquid biopsy" patented technology

The invention relates to a breast cancer plasma transporter miRNA marker and application thereof, and belongs to the technical field of biological detection. In the prior art, biomarkers for breast cancer liquid biopsy have the problems of low content, high heterogeneity, insufficient time resolution and the like, so that the detection reliability is limited. According to the invention, a specific miRNA (micro Ribonucleic Acid) marker (including one or more of let-7d-5p, miR-103a-3p and miR-22-3p) of the plasma transporter is provided. The marker can be used for preparing a breast cancer detection reagent or kit. Clinical verifications show that the miRNAs are remarkably and highly expressed in plasma migrators of breast cancer patients, the AUC value reaches 0.763-0.808, the sensitivity is 66.7%-86.7%, the specificity is 66.7%-88.3%, the miRNAs have the advantages of high signal-to-noise ratio and dynamic monitoring, and the accuracy and practicability of breast cancer detection are remarkably improved.

The application discloses an exosome small non-coding RNA molecule marker and application thereof, and belongs to the field of tumor liquid biopsy and molecular diagnosis. The exosome small non-coding RNA molecule marker is at least one of tRNA-GlyGCC-5 and sRESE; the nucleotide sequence of the tRNA-GlyGCC-5 is shown as SEQ ID NO:1; and the nucleotide sequence of the sRESE is shown as SEQ ID NO:2. The sRESE in the application is a brand new small non-coding RNA sequence, and is first discovered by the inventor, which is important for the marker of esophageal cancer and the research on disease progression mechanism. The tumor diagnosis kit provided by the application, which comprises the exosome small non-coding RNA molecule marker, is a liquid diagnosis monitoring kit with non-invasiveness, high sensitivity, high specificity and applicability to general survey or screening.

The invention discloses a postoperative recurrence monitoring system and method for bile liquid biopsy, and relates to the technical field of medical detection, and the method comprises the following steps: obtaining medication data, bile liquid data and gene data of a target object; preprocessing the medication data and the bile liquid data to generate a sampling interference index sequence, and further performing weighted fusion on the gene data by the sampling interference index sequence to obtain a mutation load index of each gene detection time point; and within the time sequence range of the gene data, performing sliding window analysis on the sampling interference index sequence to generate an abnormal chain marker sequence. According to the method, the time sequence mismatch degree is accurately quantified by constructing a time difference matrix, and a weight distribution mechanism is dynamically adjusted in combination with medication volatility, so that the generation process of the sampling interference index can adaptively reflect the influence of medication mode change on the sampling quality; the problem of interference evaluation deviation caused by mismatching of medication data and bile sampling time is effectively solved.

The invention specifically discloses application of VGF as a diagnostic biomarker for prostatic cancer, and relates to the technical field of biological medicines. The secretory protein VGF is identified to be remarkably up-regulated in prostatic fluid of a prostatic cancer patient before puncture for the first time, high expression of the secretory protein VGF is proved to be independently related to shorter progression-free lifetime and total lifetime through a public database, and a brand-new liquid biopsy marker is provided for PCa non-invasive early screening and prognosis evaluation.

The application provides a kind of nanoparticle, preparation method and its early screening related application of cancer, wherein, nanoparticle includes superparamagnetic nanometer core, cationic polymer modified on the surface of superparamagnetic nanometer core and targeted polypeptide grafted on cationic polymer, the targeted polypeptide can specifically recognize tumor specific antigen protein, and has the modular structure of rigid helix and charge repulsion sequence.The plasma low-abundance protein enrichment nanoparticle provided by the application can be used for the detection of early screening of tumor through liquid biopsy, can significantly improve the detection rate of early tumor, and has important clinical significance.

The invention provides an EGFR-TKI drug-resistant biomarker detection method based on a non-immobilized GO-SELEX screening aptamer and a kit. In the preparation process of the kit, a nucleic acid aptamer Osi-1 capable of being specifically combined with characteristic protein (Calnexin) in EGFR-TKI drug-resistant cell supernatant is obtained through a GO-SELEX technology. Furthermore, an unmarked optical sensing platform is constructed in combination with gold nanoparticles, so that rapid and sensitive detection of Calnexin is realized. The kit is suitable for early recognition of EGFR-TKI drug resistance, and can be used for clinical liquid biopsy and precise treatment monitoring.

The invention describes a novel nanoparticle coated with a Hypericum perforatum extract and a novel diagnostic kit in which such nanoparticle is used and isolates cancer cells, achieving the effective, accurate and efficient diagnosis and prognosis of different types of cancer, by use of samples from liquid biopsies.

The application relates to the technical field of biological medicine, and discloses a tumor marker micro-detection and analysis method based on liquid biopsy. The method comprises the following steps: extracting peripheral blood free DNA and performing double-end sequencing; jointly extracting multi-dimensional features such as ctDNA fragment length distribution, end sequence preference, nucleosome positioning signal and CpG methylation state from the sequencing data; constructing a feature matrix under unified genomic coordinates through space-time alignment; inputting a pre-trained cross-scale graph neural network model, taking a genomic region as a node and physical and functional proximity as an edge, learning a coupling mode of multi-modal features in a local chromatin structure, and outputting a malignant risk score; and combining a threshold to distinguish early lung cancer and benign and malignant nodules. The application comprises corresponding functional units and supports efficient parallel analysis. The system significantly improves detection sensitivity and specificity, reduces the false negative rate by 36%, and realizes non-invasive and accurate early lung cancer screening.

The present disclosure includes, among other things, methods, kits, and systems for determining a status of lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation as features of a status of lung cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci in a biological sample, e.g., cell-free DNA (cfDNA), from a liquid biopsy sample obtained or derived from a subject having lung cancer. In various embodiments, the determined status can be used, e.g., to select a treatment for lung cancer and / or to treat lung cancer.

This utility model discloses a liquid biopsy kit, belonging to the field of medical reagent storage technology. The device includes a box with an openable cover at the top and support legs at the bottom. Inside, there is a pull-out placement plate with multiple slots for different reagent tube sizes. The rear of the box has a storage compartment with a cooling mechanism, which cools the reagent tubes through a ventilation structure. The bottom of the box has a buffer plate, and each placement slot has an independent buffer pad to effectively improve placement stability. The inside of the cover has a storage compartment and elastic pads to cushion impacts in case of drops, preventing damage to the reagent tubes. This utility model has a compact structure, high storage safety, strong adaptability, and is easy to clean and maintain. It is suitable for the cold storage and transportation management of liquid samples.

The present disclosure includes, among other things, methods, kits, and systems for determining the status of MS in a subject. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that are characteristic of the status of MS. In some embodiments, differential modifications and / or differential accessibility are detected and quantified, at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with MS. In various embodiments a determined status is useful, e.g., in selecting treatment for and / or treating MS.

The invention provides a nanoparticle, a preparation method and a cancer early screening related application thereof, the nanoparticle comprises a superparamagnetic nano core, a cationic polymer modified on the surface of the superparamagnetic nano core and a targeting polypeptide grafted on the cationic polymer, the targeting polypeptide can specifically recognize a tumor specific antigen protein, and has a modular structure comprising a rigid helix and a charge repulsion sequence. The plasma low-abundance protein-enriched nanoparticles provided by the invention can be used for early screening detection of tumors through liquid biopsy, can significantly improve the detection rate of early tumors, and have important clinical significance.

This invention discloses a method and system for assessing tumor content in liquid biopsies. The method performs quality control on high-throughput sequencing data from body fluid samples, filtering germline variations, clonal hematopoietic-related variations, and sequencing errors to obtain copy number variation (CNV) information and somatic mutation characteristic information. A weighted mean squared error loss function is constructed based on the CNV information, and the tumor content is solved using a constrained gradient descent method. When the CNV signal does not meet preset judgment conditions, the system switches to the mutation characteristic module, constructing a negative log-likelihood function based on a binomial distribution based on the principal clonal cluster, and solving for the tumor content through iterative optimization. In extreme cases, a backoff mechanism is triggered. This invention combines the stability of CNV at high tumor content with the sensitivity of mutational VAF at low content, achieving adaptive assessment from low to high tumor content.

Described herein are gene features for providing prognosis, diagnosis, treatment and molecular subtype classification of cancer by genomic and epigenomic profiling, methods and compositions for determining cancer and subtypes, including breast cancer, and provide specific and sensitive detection of biomarkers of interest. Such biomarkers indicate disease pathogenesis, which provides opportunities to select treatment, including treatment regimens intended to identify responsive candidates and overcome resistance mechanisms.

The invention provides a digestive tract tumor course monitoring system. The system comprises a system control module, a first-stage detection module, a second-stage detection module, a third-stage detection module, a risk assessment module and an intervention decision module. The primary detection module is used for collecting tumor markers, images and clinical symptom data of a patient; the second-stage detection module is used for performing liquid biopsy, pathological biopsy and metabolic function evaluation on the first-stage positive patient; the third-stage detection module is used for carrying out micro-metastasis detection and immune microenvironment and genome analysis on a second-stage positive patient; the risk assessment module determines a patient risk level based on a detection result; the intervention decision module outputs intervention measures based on the risk level; the system control module manages and coordinates operation of all the modules. Each detection module automatically captures detection data by being connected with a hospital system, and judges an abnormal condition according to a set threshold value. According to the system, through a logic mechanism of grading detection and grading intervention, precise monitoring and early warning intervention on the disease course of the digestive tract tumor patient are realized.

The invention discloses a mutant gene enrichment method, a mutant gene detection method and a mutant gene detection kit based on Cas9 specific cleavage and isonucleotide magnetic beads. The method comprises the following steps: firstly, extracting free DNA; then identifying and cutting a completely matched wild type sequence by using Cas9 protein and specific sgRNA, and reserving the mutant DNA due to base mismatch; cas9 treated DNA and streptavidin magnetic beads containing a biotinylated oligonucleotide probe are incubated, guanine and cytosine in the probe are substituted by isoguanine and isocytosine respectively, and adenine and thymine are modified by locked nucleic acid, so that high-stability homodromous pairing is realized, and mutation DNA is selectively enriched; and finally, carrying out qPCR or sequencing detection on the enriched DNA. The kit has the characteristics of simplicity and convenience in operation, high specificity and high sensitivity, can be used for detecting single-base-level mutation, and is suitable for liquid biopsy, tumor early screening and genetic disease mutation detection.

Various embodiments are directed to the analysis of fragmentation patterns of cell-free DNA (cfDNA) circulating in cerebrospinal fluid (CSF) and the potential applications. CSF is an important liquid biopsy sample used to study the central nervous system and related disorders, such as infection and malignancies. The characterization of fragmentation patterns of cfDNA in CSF includes the size profile, end motif, cleavage profiles, and the determination of epigenetic features, including methylation. Various applications can use one or more properties of fragmentation pattern, for example, in the determination of the proportional contribution of a particular cell types in the CSF cfDNA pool. Another purpose is the diagnosis of pathology in the central nervous system, by the detection of clinically relevant DNA (e.g., tumor fraction, pathogen). DNA fragments in CSF can be analyzed in various ways, including using short-read sequencing, and / or long-read sequencer technologies.

The present disclosure provides methods and compositions for improving the quantity and quality of cfDNAs in a bodily fluid of a subject by inhibiting the nuclease activity in the subject. The methods and compositions disclosed herein are particularly useful for subjects who have been identified that liquid biopsies are needed.

The present application relates to the technical field of medical detection, and particularly relates to a marker combination, a primer probe combination, a kit and application for detecting multiple subtypes of ovarian cancer and borderline ovarian tumors. The marker combination comprises at least 3 of the following differential methylation regions: a differential methylation region of IFFO1, a differential methylation region of TFAP2E-AS1, a differential methylation region of WNT6, and a differential methylation region of AC104801.1. The present application can comprehensively cover the detection of multiple subtypes of ovarian cancer and borderline ovarian tumors, is suitable for liquid biopsy, and has high sensitivity and high specificity.

Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.

This invention discloses a composite nanozyme and a kit for simultaneous recognition of multiple exosomes. The kit includes an aptamer / composite nanozyme solution, exosome standards, TMB substrate solution, H2O2 solution, and 96-well plate enzyme labeling strips. This invention innovatively utilizes Ti3C2T... x A nanozyme (MX-MnNF) formed by combining MXene nanosheets and MnO2 nanoflowers was constructed, and a colorimetric sensor array was built by modifying it with three aptamers: EpCAM, MUC1, and HER2. Based on the peroxidase-like activity of the nanozyme, it can catalyze the TMB-H2O2 reaction to produce color changes, enabling the simultaneous recognition of multiple exosomes. This method can complete the detection within 10 minutes, with a detection sensitivity of up to 10 particles / mL and an accuracy of up to 95% for clinical samples. It has the advantages of simple operation, rapid detection, and high sensitivity, providing a new technical means for tumor liquid biopsy.

The embodiment of the application provides a kind of multi-modal gastric cancer neoadjuvant therapy curative effect prediction method, device and equipment based on image and liquid biopsy genomic data and storage medium, it is related to gastric cancer neoadjuvant therapy technical field, the method comprises: obtaining the image data of tumor focus of gastric cancer patient before receiving gastric cancer neoadjuvant therapy, liquid biopsy genomic data and clinical baseline data;First key feature is extracted from image data and input into first prediction model to obtain first curative effect;Second key feature is extracted from genomic data and input into second prediction model to obtain second curative effect;According to first curative effect and second curative effect, the predicted curative effect of gastric cancer patient after receiving gastric cancer neoadjuvant therapy is determined.The above-mentioned three kinds of information of the gastric cancer patient to be predicted are input into the curative effect prediction model trained based on the information of sample gastric cancer patient by the above scheme, i.e.The curative effect of the gastric cancer patient to be predicted after receiving gastric cancer neoadjuvant therapy can be predicted.

The present disclosure includes, among other things, methods, kits, and systems for determining the status of lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of the status of lung cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with lung cancer. In various embodiments a determined status is useful, e.g., in selecting treatment for and / or treating a lung cancer.

Methods are disclosed for predicting a likelihood of developing a severe immune-related adverse event (irAE) associated with the administration of an immunotherapy in a melanoma patient based on abundances of activated CD4 memory T cells and / or diversities of T cell receptors (TCR) within a peripheral blood sample obtained from the patient.

Methods for screening subjects who are at an elevated risk of developing cancer due to pathogenic germline variants or hereditary cancer syndrome (HCS). In some aspects, the methods include determining a baseline cancer signal from the subject and performing subsequent diagnostic tests, such as liquid biopsies, at subsequent timepoints to determine the presence or absence of cancer in the subject based on the level and rate of change of the cancer signal. The methods can monitor the level and rate of cancer signal over time and allow are more frequent testing intervals. The methods may also comprise using "gold-standard" screening approaches, such as colonoscopies, in combination with liquid biopsies to detect primary (high risk) cancers and secondary cancers (elevated risk) in the subject. In some embodiments, follow-on assays can be personalized based on the type of pathogenic germline variant(s) / disease suspected or determined to be present in the subject.

The present application relates to a kind of biomarkers for Parkinson or early diagnosis of Parkinson, including the combination of PRKD2, TULP2, ALKAL2, RUFY1, HDAC9, LINC01600, EXT2, ARHGAP24 and CCDC102B.The biomarker provided by the present application can effectively diagnose Parkinson, the sensitivity and specificity reach 0.903, 0.792 respectively, and the AUC value is 0.854;At the same time, the AUC value for differential diagnosis of Parkinson similar diseases is 0.856.According to the biomarker for diagnosis, compared with some liquid biopsy markers currently available, it has the advantages of safe and non-invasive, easy to obtain sample, high accuracy, easy to operate and the like, and provides accurate judgment for early diagnosis of Parkinson.

This invention belongs to the field of biomedical technology, specifically relating to the application of a pharmaceutical composition consisting of denosumab combined with an immune checkpoint inhibitor in the preparation of a drug for treating KRAS-mutant advanced non-small cell lung cancer (NSCLC). Addressing the problems of high toxicity, limited efficacy, and lack of effective prognostic biomarkers in existing maintenance therapy for KRAS-mutant advanced NSCLC, this invention experimentally demonstrates that maintenance therapy with denosumab combined with a PD-1 / PD-L1 inhibitor can significantly prolong overall survival in patients with KRAS-mutant advanced NSCLC who have not progressed after 4-6 cycles of first-line immunochemotherapy, with a lower incidence of treatment-related adverse events and better safety, especially in patients with KRAS-G12C mutations. Furthermore, this invention discovers that plasma CCER2 can serve as a prognostic biomarker. This invention provides a new, low-toxicity, high-benefit strategy for KRAS-mutant advanced NSCLC and also provides a liquid biopsy biomarker that can be used for patient stratification, possessing significant clinical application value.

The present invention provides a method for detecting, assessing, and monitoring pancreatic cancer without requiring surgical biopsy or other invasive means. The method of the present invention is a “liquid biopsy”-based technique that relies on analysis including the examination of several feature types, which may include epigenetic signatures, particularly 5-hydroxymethylcytosine signatures; 5hmC-containing fragment counts in annotated CpG island genomic regions; 5hmC-containing fragment counts in CTCF-binding regions; 5hmC-containing fragment counts in annotated enhancer regions; 5hmC-containing fragment counts in annotated gene body regions; and 5hmC-containing fragment counts in annotated 3'-UTR genomic regions.

Disclosed herein are methods, compositions, and devices for diagnosing and treating cancer. The methods include sequencing a set of regions in cell-free nucleic acid molecules and detecting one or more biomarkers indicative of cancer and cancer subtype typing ability.

The invention discloses a tumor metastasis risk assessment method and system based on circulating tumor DNA (ctDNA) spatial heterogeneity. The core of the method is as follows: blood samples of at least two different anatomical sites (such as peripheral veins and tumor drainage veins) of the same subject are obtained at the same time, and ctDNA in the samples is subjected to sequencing analysis; calculating characteristic data (such as a relative abundance ratio) representing ctDNA spatial distribution based on the mutation abundance difference between different parts; and finally, inputting the feature data into a pre-trained metastasis risk assessment model, and outputting a quantitative tumor metastasis risk score. According to the method, the limitation of traditional single-point liquid biopsy is broken through, the detection sensitivity of tiny metastases can be remarkably improved by utilizing the spatial distribution information of the ctDNA, potential metastasis positioning information is provided, and powerful technical support is provided for accurate diagnosis and treatment decision of tumor patients.